Clearline Capital LP Purchases Shares of 502,683 Avantor, Inc. $AVTR

Clearline Capital LP purchased a new stake in shares of Avantor, Inc. (NYSE:AVTR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 502,683 shares of the company’s stock, valued at approximately $5,761,000.

Other hedge funds have also bought and sold shares of the company. Natixis Advisors LLC grew its holdings in Avantor by 124.8% during the third quarter. Natixis Advisors LLC now owns 1,907,077 shares of the company’s stock valued at $23,800,000 after purchasing an additional 1,058,617 shares during the period. Quantbot Technologies LP boosted its stake in shares of Avantor by 1,333.0% in the third quarter. Quantbot Technologies LP now owns 246,494 shares of the company’s stock worth $3,076,000 after acquiring an additional 229,293 shares during the period. Greenhaven Associates Inc. boosted its stake in shares of Avantor by 12.0% in the fourth quarter. Greenhaven Associates Inc. now owns 20,500,653 shares of the company’s stock worth $234,937,000 after acquiring an additional 2,189,083 shares during the period. London Co. of Virginia bought a new position in shares of Avantor in the third quarter worth about $159,669,000. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Avantor by 83.0% in the third quarter. Orion Porfolio Solutions LLC now owns 285,419 shares of the company’s stock worth $3,562,000 after acquiring an additional 129,480 shares during the period. Institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Simon Dingemans acquired 25,000 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were acquired at an average cost of $8.14 per share, for a total transaction of $203,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at approximately $203,500. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gregory T. Lucier acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were bought at an average price of $8.32 per share, for a total transaction of $83,200.00. Following the completion of the transaction, the director owned 60,000 shares of the company’s stock, valued at approximately $499,200. This trade represents a 20.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.28% of the company’s stock.

Avantor Price Performance

Shares of Avantor stock opened at $9.46 on Thursday. The stock has a 50 day moving average of $8.48 and a 200 day moving average of $9.57. Avantor, Inc. has a 12 month low of $7.26 and a 12 month high of $15.93. The firm has a market cap of $6.46 billion, a PE ratio of -11.67, a PEG ratio of 5.55 and a beta of 0.97. The company has a current ratio of 1.76, a quick ratio of 1.17 and a debt-to-equity ratio of 0.68.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Avantor had a positive return on equity of 9.95% and a negative net margin of 8.42%.The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period in the prior year, the company earned $0.23 earnings per share. The firm’s revenue was up .0% on a year-over-year basis. On average, research analysts expect that Avantor, Inc. will post 0.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AVTR has been the subject of a number of recent analyst reports. Royal Bank Of Canada initiated coverage on Avantor in a research note on Thursday, May 14th. They issued a “sector perform” rating and a $9.00 price objective for the company. Citigroup dropped their price objective on Avantor from $11.00 to $9.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Zacks Research raised Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Wolfe Research lowered Avantor to an “underperform” rating and set a $7.00 price objective for the company. in a research note on Monday, June 1st. Finally, Wall Street Zen lowered Avantor from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $10.57.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.